Literature DB >> 28025815

Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.

Catc Lunenburg1, J J Swen2, H-J Guchelaar2, H Gelderblom3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28025815     DOI： 10.1007/s12029-016-9908-3

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  10 in total

1.  Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.

Authors:  Saranya Kodali; Venu Bathini; Paul Rava; Eswar Tipirneni
Journal:  J Gastrointest Cancer       Date:  2017-03

Review 2.  Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.

Authors:  Carin A T C Lunenburg; Linda M Henricks; Henk-Jan Guchelaar; Jesse J Swen; Maarten J Deenen; Jan H M Schellens; Hans Gelderblom
Journal:  Eur J Cancer       Date:  2015-12-21       Impact factor: 9.162

Review 3.  Pharmacogenetics: from bench to byte--an update of guidelines.

Authors:  J J Swen; M Nijenhuis; A de Boer; L Grandia; A H Maitland-van der Zee; H Mulder; G A P J M Rongen; R H N van Schaik; T Schalekamp; D J Touw; J van der Weide; B Wilffert; V H M Deneer; H-J Guchelaar
Journal:  Clin Pharmacol Ther       Date:  2011-03-16       Impact factor: 6.875

4.  Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule.

Authors:  Paul Christiaan Dirk Bank; Henk-Jan Guchelaar; Joachim Jesse Swen
Journal:  Intern Emerg Med       Date:  2013-12-06       Impact factor: 3.397

5.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Authors:  L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

6.  Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.

Authors:  Elena Magnani; Enrico Farnetti; Davide Nicoli; Bruno Casali; Luisa Savoldi; Chiara Focaccetti; Corrado Boni; Adriana Albini; Maria Banzi
Journal:  Intern Emerg Med       Date:  2013-04-13       Impact factor: 3.397

7.  Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.

Authors:  Maarten J Deenen; Didier Meulendijks; Annemieke Cats; Marjolein K Sechterberger; Johan L Severens; Henk Boot; Paul H Smits; Hilde Rosing; Caroline M P W Mandigers; Marcel Soesan; Jos H Beijnen; Jan H M Schellens
Journal:  J Clin Oncol       Date:  2015-11-16       Impact factor: 44.544

8.  Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.

Authors:  K E Caudle; C F Thorn; T E Klein; J J Swen; H L McLeod; R B Diasio; M Schwab
Journal:  Clin Pharmacol Ther       Date:  2013-08-29       Impact factor: 6.875

9.  DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.

Authors:  Salvatore Terrazzino; Sarah Cargnin; Marzia Del Re; Romano Danesi; Pier Luigi Canonico; Armando A Genazzani
Journal:  Pharmacogenomics       Date:  2013-08       Impact factor: 2.533

Review 10.  Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

Authors:  Dan Rosmarin; Claire Palles; David Church; Enric Domingo; Angela Jones; Elaine Johnstone; Haitao Wang; Sharon Love; Patrick Julier; Claire Scudder; George Nicholson; Anna Gonzalez-Neira; Miguel Martin; Daniel Sargent; Erin Green; Howard McLeod; Ulrich M Zanger; Matthias Schwab; Michael Braun; Matthew Seymour; Lindsay Thompson; Benjamin Lacas; Valérie Boige; Nuria Ribelles; Shoaib Afzal; Henrik Enghusen; Søren Astrup Jensen; Marie-Christine Etienne-Grimaldi; Gérard Milano; Mia Wadelius; Bengt Glimelius; Hans Garmo; Milena Gusella; Thierry Lecomte; Pierre Laurent-Puig; Eva Martinez-Balibrea; Rohini Sharma; Jesus Garcia-Foncillas; Zdenek Kleibl; Alain Morel; Jean-Pierre Pignon; Rachel Midgley; David Kerr; Ian Tomlinson
Journal:  J Clin Oncol       Date:  2014-03-03       Impact factor: 50.717
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.